Clinical Trial

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-09.
Status change: Not Yet Recruiting → Recruiting 2024-03-04
Trial Details
NCT Number NCT05910177
Lead Sponsor Fujian Cancer Hospital
Conditions Carcinoma, Cervix Carcinoma
Enrollment 30 participants
Start Date 2023-12-28
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-06